title: Antibiotic prophylaxis for patients undergoing transurethral resection of the prostate.
abstract: OBJECTIVE
  To evaluate the prevention of urinary tract infections (UTIs) after transurethral resection of the prostate (TURP) in a prospective randomized study using a quinolone antibiotic (fleroxacin) to compare the efficacy of: (1) a single oral dose, (2) a single intravenous (IV) dose, and (3) an extended regimen consisting of an initial IV dose followed by oral therapy until removal of the urinary catheter, but for less than 6 days.
  
  
  METHODS
  We excluded from study patients who received antimicrobial agents within 48 hours of surgery. Single-dose prophylaxis consisted of 400 mg of fleroxacin given either orally or intravenously. The extended regimen consisted of an initial 400 mg IV dose followed by 400 mg oral each day (patients older than 75 years, or with a creatinine clearance less than 40 mL/min, received 200 mg/day). UTI was defined as clinical evidence of infection plus the presence of more than 10 white blood cells (WBC)/mm3 in any urine specimen plus the presence of more than 10(4) cfu/mL in midstream urine specimens or more than 10(2) cfu/mL in catheter specimens.
  
  
  RESULTS
  Prior to TURP, 30% (25/84) of the patients had a urethral catheter in situ and 12% (3/25) of these patients had bacteriuria. Only 1 patient developed a UTI and that was 22 days after a TURP (intergroup comparisons, Fisher's exact test greater than 0.05). There were no instances of urosepsis.
  
  
  CONCLUSIONS
  A single oral dose of a fluoroquinolone agent provided optimum prophylaxis for patients undergoing TURP.
authors.affiliation: University Department of Surgery, Royal Perth Hospital, Perth, Australia.
authors.forename: J C
authors.initials: JC
authors.lastname: Hall
authors.forename: K J
authors.initials: KJ
authors.lastname: Christiansen
authors.forename: P
authors.initials: P
authors.lastname: England
authors.forename: A I
authors.initials: AI
authors.lastname: Low
authors.forename: P J
authors.initials: PJ
authors.lastname: McRae
authors.forename: J
authors.initials: J
authors.lastname: Mander
authors.forename: T A
authors.initials: TA
authors.lastname: Taylor
authors.forename: J L
authors.initials: JL
authors.lastname: Hall
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage*; D019072:Antibiotic Prophylaxis; D002986:Clinical Trials as Topic; D016576:Fleroxacin / Q000008:administration & dosage*; D006801:Humans; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011468:Prostatectomy; D014552:Urinary Tract Infections / Q000517:prevention & control*
chemical_list: D000890:Anti-Infective Agents; D016576:Fleroxacin